 NEWTOWN, Pa., Jan. 07, 2021 GLOBE NEWSWIRE -- Onconova Therapeutics, Inc. NASDAQ: ONTX Onconova, a biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced that it has entered into a definitive purchase agreement with certain institutional accredited investors to purchase in a registered direct offering 19,550,562 shares of its common stock at a purchase price of 0.445 per share. 